Educational information

This video was recorded during an expert meeting among cardiologists and internists, focussing on the topic of 'LDL-c & PCSK9 inhibition in high CV risk patients - Balancing Science, Guidelines and Daily Cardiology Practice'.

The objectives of the meeting were to:

• Review recent outcome data with PCSK9 inhibitors in the clinical management of patients who had a recent MI
• Discuss the importance of reaching LDL-c targets in patients post MI
• Provide a European expert perspective on the current challenges of reaching LDL-c targets and use of PCSK9 inhibitors in clinical cardiology
• Define key challenges, needs and goals for education to ensure the implications of new outcome trials like FOURIER and ODYSSEY-outcomes will be adopted in post MI patients
• Develop a consensus and clinical guidance on lowering LDL-c in post MI patients

Other topics covered in this series

Other lectures part of this educational series are:

• What is the science and outcome supporting lower LDL-c targets - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Lluis Masana, MD, Reus, Spain
• The guidelines in need of a major change? - Prof. Kausik Ray, MD, London, UK, & Prof. François Mach, MD, Geneva, Switzerland
• What are the key issues and challenges impacting clinical management with novel therapeutics? - Prof. Kausik Ray, MD, London, UK, & Prof. Gilles Montalescot, MD, Paris, France
• Progressive CAD despite low LDL-c an elusive disease - Prof. Kausik Ray, MD, London, UK, & Prof. Wouter Jukema, MD, Leiden, The Netherlands
• How are the guidelines for progressive CAD guiding us in clinical practice? - Prof. John Kastelein, MD, Amsterdam, The Netherlands, & Prof. Ulf Landmesser, MD, Berlin, Germany
• FH in clinical cardiology: highly prevalent. Challenges for screening and treatment of FH patients - Prof. Kausik Ray, MD, London, UK, & Prof. Kees Hovingh, MD, Amsterdam, The Netherlands

Faculty

Prof. John J.P. Kastelein, MD, internist, Professor of Medicine, Department of Vascular Medicine; Strategic Chair of Genetics of Cardiovascular Disease at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands

Prof. Chris Packard, Research and Development Director, NHS Greater Glasgow & Clyde Health Board; Honorary professor of vascular biochemistry, University of Glasgow, Scotland, United Kingdom

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding for the Expert Meeting was provided by an unrestricted educational grant from Amgen. The sponsor did not attend and influence the video recording.